Nyrada Inc

Nyrada Inc is an innovative biotechnology company dedicated to the discovery and development of first-in-class small molecule drugs outside oncology. As a clinical stage organization listed on the Australian Securities Exchange (ASX: NYR), Nyrada is focused on addressing significant unmet clinical needs through its development programs. The company's flagship product, Xolatryp®, is designed for cardioprotection and neuroprotection, with promising results from various preclinical studies.

Notably, Xolatryp demonstrated a 42% neuroprotective effect in stroke studies and an 86% cardioprotective effect in myocardial ischemic-reperfusion injury. Furthermore, it has shown the potential to reduce arrhythmias by 90% in subsequent studies. Nyrada is advancing to its first Phase Ia clinical trial, which successfully established the safety and tolerability of Xolatryp in healthy volunteers.

The company is now preparing for a Phase IIa clinical trial focused on patients experiencing ST-Elevation Myocardial Infarction (STEMI). Nyrada aims to become a high-growth pharmaceutical leader in early-stage drug development